Summary-Fifty-three solid and 33 fine-needle aspirate (FNA) samples (20 paired) of human breast carcinomas were examined by flow cytometry. Experiments were conducted to assess whether FNA samples were phenotypically representative of the solid tumour. Quantification of oestrogen receptor (ER), epidermal growth factor receptor (EGFR). c-erbB-2 receptor levels and ploidy were examined on the total and cytokeratin-positive cell populations. The absolute number of molecules of cytokeratin per cell expressed on the FNA (n = 33) and solid tumour (n = 53) samples showed no significant difference, but, on a proportional basis. there was a significant difference between the two samples (P = 0.004). with lower expression exhibited by the FNAs. Examination of paired data showed no significant difference in the percentage of cytokeratinpositive cells (P = 0.51) or in the number of cytokeratin molecules expressed (P = 0.25). While the correlation for ER expression between paired tumour and FNA samples in the absence of cytokeratin gating was P = 0.06. r = 0.18. clear correlation was shown when a cytokeratin gate was used (P =0.005. r = 0.4). Repeating this experiment for EGFR. it was found that no correlation was seen between FNA and solid tumour (P= 0.2. r = 0.14) in ungated populations. but use of the cytokeratin gate improved the correlation (P= 0.05. r = 0.3). A similar finding was seen with c-erbB-2 expression (P = 0.2. r = 0.1) without cytokeratin gating and when it was employed (P = 0.05. r = 0.4). Ploidy data showed concordance in 18/20 cases. Three cases of aneuploidy were missed by FNA. and this was because of an insufficient number of cells for analysis. The presented data suggest that FNAs are representative of solid tumours and may be useful for measuring receptor levels on clinical material when cytokeratin gating is used. However, observation by light microscopy is still necessary to confirm the presence of tumour cells in FNAs subjected to flow cytometry.
ploidy Fine-needle aspiration of breast tumours is being used increasingly as a diagnostic modality. For a high level of diagnostic accuracy both aspirator and cytologist must be highly experienced (Brown et al., 1991; Powles et al., 1991) .
Little has been done to assess potentially important prognostic markers within such samples using flow cytometry. Immunohistochemical studies of breast tumours are usually restricted to frozen or paraffin-embedded sections of postoperative tissue. and solid tumour sampling usually occurs after surgery. Flow cytometric studies of these tumours are therefore reliant on rapid processing by the histopathologist.
Of more significance, information obtained from the tumour is only available after surgery and treatment has occurred. FNA sampling allows a 'preview' of cancers and, if suitable prognostic markers are examined, could potentially influence treatment. A further reason for using FNAs is the fact that tumours are being detected at an early stage, are small and the quantity of material available may be limited. The ability to examine FNAs at this early stage may offer potential benefits to both the surgeon and the pathologist.
It has been reported that examination of solid tumours for epidermal growth factor receptor (EGFR; Nicholson et al., 1988; Sainsbury et al., 1985) , oestrogen receptor (ER; Howell et al., 1984) , c-erbB-2 (Berger et Paik et al., 1990; Gullick et al., 1991; Perren, 1991) and DNA (Yuan et al., 1991) are of prognostic use and can be assessed by flow cytometry. Both ER and EGFR, measured by flow cytometry, have been shown to compare well with conventional radioligand binding assays (Brockhof et al.. 1994 : Brotherick et al.. 1994a , 1995 Positive oestrogen receptor status has been shown to be linked to node-negative disease, indicating superior prognosis, and predicts for a lower histological grade (Howell et al., 1984) . Overexpression of c-erbB-2 has been shown to be linked with poor prognosis (Wright et al., 1989; Perren, 1991) , shorter relapse-free survival, adverse nodal status (Slamon et al., 1987; Gullick et al., 1991) and poor histological grade (Berger et al., 1988) . The presence of EGFR has been identified as a marker of poor prognosis, showing a positive correlation with tumour grade (Sainsbury et al., 1985) . Ploidy has been linked to prognostic survival in nodenegative breast cancer (Yuan et al.. 1991 al., 1986) . Cytokeratin gating has been shown to be of some use in removing non-epithelial cell 'noise' from data obtained by flow cytometry (Ferrero et al., 1990) . This has enabled the detection of weakly expressed antigens such as ER (Brothenrck et al., 1995 733 added, mixed well and incubated for 20 min at 4°C followed by washing in Isoton II (Coulter) using a preprogrammed cell wash cycle. Cell pellets were resuspended in 0.5 ml of Isoton II (Coulter) before examination on a FACScan flow cytometer (Becton Dickinson) using prestored settings.
Assessment ofploidy
To tube 3 (labelled with 5D3-FITC) propidium iodide and RNAse A (in Isoton II) were added to produce final concentrations of 0.025 mg ml1' and 1 mg ml-' respectively. Ploidy was assessed by flow cytometry using prestored settings utilising the doublet discriminatory module (DDM). Linearity of the amplifier and FACScan settings were checked using chicken red blood cells (Sigma). Instrument verification and quality control were carried out using DNA QC particles (Becton Dickinson) according to the manufacturer's instructions.
Antibody standardisation
Antibody standardisation was carred out using Quantum Simply Cellular bead standards (QSC, Research Triangle Park, NC, USA) as previously described (Brotherick et al., 1994a Comparsn o markers for FNA and soid breast tumows Brotherck et ad 736 Cytokeratin levels have been measured on many tumours (Angus et al., 1987; Ferrero et al., 1990; Brotherick et al., 1994b) and have been shown to be of importance in gating out debris and contaminating stromal and lymphoid cells (Ferrero et al., 1990; Brotherick et al.. 1995 (Brotherick et al.. 1995 (Brockhof et al.. 1994; Brotherick et al.. 1994a) . Expression of c-erbB-2 has been measured by flow cytometry (StAl et al.. 1994) .
However c-erbB-2 expression, in terms of number of molecules. has not been reported. although from our work we have shown that around 3200 molecules per cell appears to be the threshold above which positive cancers are determined (Brotherick et al.. 1994b ).
On examining the total tumour population alone. with and without cytokeratin gating, a good correlation for ER expression was found. Similarly, on the same aspirate a close correlation for ER expression with or without cytokeratin gating was seen. This reflects the reproducibility of the analysis performed. However. when paired samples were analysed we found that cytokeratin gating was important for the FNA to be representative of the solid tumour. This finding is reflected in Figures Ic and d . EGFR and c-erbB-2 expression both followed this pattern (Figures 2 and 3 Ferrero et al. (1990) .
who have assessed the use of cytokeratin staining in the assessment of DNA content.
Use of FNA samples of breast cancers. while presenting some problems. does not appear to be representative of the underlying solid tumour. Despite the lower levels of detection of ER. EGFR and c-erbB-2. these problems are surmountable by the use of regulated cut-off points above which positivity of a tumour is determined. Such levels would need to be assessed in a large prospective study before they could be applied to clinical samples. The methodology would allow rapid detection of markers on breast tumours as near to the time of clinical presentation and cytological diagnosis as possible.
